Taligen Therapeutics
Focused on the R&D of novel protein therapeutics for the treatment of inflammatory conditions and diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$111m (Public information from Jan 2011)
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$3.8m | Series A | ||
$65.0m | Series B | ||
| N/A | $10.0m | Series B | |
$111m Valuation: $111m | Acquisition | ||
| Total Funding | $78.8m | ||
Related Content
Recent News about Taligen Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.